FreeTheAI

Tempus AI Subsidiary Ambry Genetics Launches Genome Sequencing Test Solution

MixedMedium impact
TEM$67.99 −4.14%

Ambry Genetics, a clinical genomic testing business owned by Tempus AI, Inc. (NASDAQ:TEM), launched GenomeNext and GenomeReveal on Tuesday. The comprehensive whole genome sequencing solution aims to help healthcare providers diagnose patients with rare conditions who often spend years seeking answers.

The testing system combines DNA sequencing with RNA analysis to clarify uncertain findings and uses a pangenome reference to capture diverse human genetic variations. In addition, the testing includes a program that automatically re-evaluates patient data as genetic discoveries progress. Past laboratory testing showed proactive reanalysis delivered positive updates in 5 percent of previously negative or inconclusive cases.

Investors and healthcare professionals will monitor how effectively the new diagnostic platform expands commercial adoption and improves diagnostic accuracy across broader patient populations. Shares of Tempus AI, Inc. were down 4.14 percent to $67.99 in recent trading.

Key points

  • Ambry Genetics, a subsidiary of Tempus AI, Inc. (NASDAQ:TEM), introduced a whole genome sequencing tool named GenomeNext and GenomeReveal.
  • The tool combines DNA and RNA sequencing with a pangenome reference to improve variant identification across diverse ancestral backgrounds.
  • A built-in program continuously re-analyzes patient data as scientific understanding grows, which historically yielded positive updates in 5% of uncertain cases.
  • Shares of Tempus AI, Inc. declined 4.14% to $67.99 following the release.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is GenomeNext by Ambry Genetics?

GenomeNext is a whole genome sequencing test solution developed by Ambry Genetics to help diagnose rare diseases by combining DNA sequencing, RNA analysis, and continuous data re-evaluation.

Who owns Ambry Genetics?

Ambry Genetics is a clinical genomic testing company that operates as a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM).

How does continuous data reanalysis work in GenomeNext?

Through the Patient for Life program, patient genetic data is proactively re-evaluated as medical knowledge advances, which has previously yielded positive reclassifications in 5 percent of uncertain cases.